Back to Newsroom
Back to Newsroom

ProPhotonix Limited Announces Results for the Year Ended December 31, 2019

Thursday, 27 August 2020 02:00 AM

ProPhotonix Limited

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

SALEM, NH / ACCESSWIRE / August 27, 2020 / ProPhotonix Limited (London Stock Exchange - AIM:PPIX,) (OTC PINK:STKR), a leading technology designer and manufacturer of LED illumination systems and laser diode modules, today announces its 2019 financial results and notice of availability on the Company's web site.

2019 Summary Results

Revenue for 2019 was $14.98 million (2018: $16.40 million). Operating profit was $1.1 million (2018: loss $1.0 million) mainly due to a stock compensation benefit from the lack of attainment of the vesting criteria on stock options ($1.2 million) versus the expense to the Income Statement in 2018 of $1.1 million. Excluding the effect of stock compensation benefit/expense, the net loss in FY19 was $0.157 million (2018: loss $0.242 million). Cash and cash equivalents at December 31, 2019 was $1.5 million (2018: $1.9 million). Detailed financial results and notes follow.

Shareholders are advised that the Auditors Opinion, while unqualified, contains a material uncertainty as to going concern, due to the matters disclosed in note 1 to the financial statements. The details of the Auditors Opinion are contained the Annual Report and Accounts which will be available on the Company's website.

Posting of Results

The Company will publish and post its final audited results for the year ended 31 December 2019 on or before September 30, 2020. The Annual Report and Accounts will be available on the Company's website on or before September 3, 2020, at www.prophotonix.com.

For further information:

ProPhotonix Limited

 

Tim Losik

President and CEO
Tel: +1 603 893 8778
Email: [email protected]

WH Ireland Limited

 

Katy Mitchell
Matthew Chan

Nominated Adviser and Broker
Tel: +44 (0) 20 7220 1666

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

Click on, or paste the following link into your web browser, to view the full announcement.

http://www.rns-pdf.londonstockexchange.com/rns/2592X_1-2020-8-26.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: ProPhotonix Limited

Topic:
Regulatory
Back to newsroom
Back to Newsroom
Share by: